{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:39:29Z","timestamp":1787243969105,"version":"build-2736575974"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2022,3,22]],"date-time":"2022-03-22T00:00:00Z","timestamp":1647907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,3,22]],"date-time":"2022-03-22T00:00:00Z","timestamp":1647907200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1007\/s10067-022-06130-1","type":"journal-article","created":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T21:04:47Z","timestamp":1647896687000},"page":"2233-2237","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Efficacy of canakinumab on AA amyloidosis in late-onset NLRP3-associated autoinflammatory disease with an I574F somatic mosaic mutation"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1020-0108","authenticated-orcid":false,"given":"Takahiro","family":"Itamiya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5890-3606","authenticated-orcid":false,"given":"Toshihiko","family":"Komai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0968-0183","authenticated-orcid":false,"given":"Hiroko","family":"Kanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1316-8035","authenticated-orcid":false,"given":"Yasuo","family":"Nagafuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyangri","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9131-5408","authenticated-orcid":false,"given":"Shota","family":"Shibata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2975-7309","authenticated-orcid":false,"given":"Hiroyuki","family":"Ishiura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1536-0303","authenticated-orcid":false,"given":"Hirofumi","family":"Shoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0717-1123","authenticated-orcid":false,"given":"Tatsushi","family":"Toda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7276-5254","authenticated-orcid":false,"given":"Keishi","family":"Fujio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,22]]},"reference":[{"key":"6130_CR1","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1136\/annrheumdis-2017-212515","volume":"77","author":"E Ben-Chetrit","year":"2018","unstructured":"Ben-Chetrit E, Gattorno M, Gul A et al (2018) Consensus proposal for taxonomy and definition of the autoinflammatory diseases (AIDs): a Delphi study. Ann Rheum Dis 77:1558\u20131565. https:\/\/doi.org\/10.1136\/annrheumdis-2017-212515","journal-title":"Ann Rheum Dis"},{"key":"6130_CR2","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.jpeds.2010.02.040","volume":"157","author":"L Lepore","year":"2010","unstructured":"Lepore L, Paloni G, Caorsi R et al (2010) Follow-up and quality of life of patients with cryopyrin-associated periodic syndromes treated with anakinra. J Pediatr 157:310-315.e311. https:\/\/doi.org\/10.1016\/j.jpeds.2010.02.040","journal-title":"J Pediatr"},{"key":"6130_CR3","doi-asserted-by":"publisher","first-page":"3625","DOI":"10.1002\/art.30512","volume":"63","author":"N Tanaka","year":"2011","unstructured":"Tanaka N, Izawa K, Saito MK et al (2011) High incidence of NLRP3 somatic mosaicism in patients with chronic infantile neurologic, cutaneous, articular syndrome: results of an international multicenter collaborative study. Arthritis Rheum 63:3625\u20133632. https:\/\/doi.org\/10.1002\/art.30512","journal-title":"Arthritis Rheum"},{"key":"6130_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2019.11.035","author":"C Louvrier","year":"2019","unstructured":"Louvrier C, Assrawi E, El Khouri E et al (2019) NLRP3-associated autoinflammatory diseases: phenotypic and molecular characteristics of germline versus somatic mutations. J Allergy Clin Immunol. https:\/\/doi.org\/10.1016\/j.jaci.2019.11.035","journal-title":"J Allergy Clin Immunol"},{"key":"6130_CR5","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1186\/s13023-017-0720-3","volume":"12","author":"R Papa","year":"2017","unstructured":"Papa R, Doglio M, Lachmann HJ et al (2017) A web-based collection of genotype-phenotype associations in hereditary recurrent fevers from the Eurofever registry. Orphanet J Rare Dis 12:167. https:\/\/doi.org\/10.1186\/s13023-017-0720-3","journal-title":"Orphanet J Rare Dis"},{"key":"6130_CR6","first-page":"S115","volume":"34","author":"FK Eroglu","year":"2016","unstructured":"Eroglu FK, Kasapcopur O, Be\u015fba\u015f N et al (2016) Genetic and clinical features of cryopyrin-associated periodic syndromes in Turkish children. Clin Exp Rheumatol 34:S115-s120","journal-title":"Clin Exp Rheumatol"},{"key":"6130_CR7","doi-asserted-by":"publisher","first-page":"266","DOI":"10.3265\/Nefrologia.pre2012.Oct.11775","volume":"33","author":"L Bola\u00f1os","year":"2013","unstructured":"Bola\u00f1os L, Mosquera-Reboredo JM, Cao M et al (2013) Renal and thyroid amyloidosis secondary tocryopyrin-associated periodic syndrome(Muckle-Wells syndrome) (NLRP3 mutation). Nefrologia 33:266\u2013271. https:\/\/doi.org\/10.3265\/Nefrologia.pre2012.Oct.11775","journal-title":"Nefrologia"},{"key":"6130_CR8","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1007\/s10067-013-2481-2","volume":"34","author":"R Scarpioni","year":"2015","unstructured":"Scarpioni R, Rigante D, Cantarini L et al (2015) Renal involvement in secondary amyloidosis of Muckle-Wells syndrome: marked improvement of renal function and reduction of proteinuria after therapy with human anti-interleukin-1beta monoclonal antibody canakinumab. Clin Rheumatol 34:1311\u20131316. https:\/\/doi.org\/10.1007\/s10067-013-2481-2","journal-title":"Clin Rheumatol"},{"key":"6130_CR9","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1007\/s00467-015-3249-5","volume":"31","author":"R Topaloglu","year":"2016","unstructured":"Topaloglu R, Batu ED, Orhan D et al (2016) Anti-interleukin 1 treatment in secondary amyloidosis associated with autoinflammatory diseases. Pediatr Nephrol 31:633\u2013640. https:\/\/doi.org\/10.1007\/s00467-015-3249-5","journal-title":"Pediatr Nephrol"},{"key":"6130_CR10","doi-asserted-by":"publisher","first-page":"149","DOI":"10.5606\/ArchRheumatol.2020.7378","volume":"35","author":"U \u0130lgen","year":"2020","unstructured":"\u0130lgen U, K\u00dc\u00c7\u00dck\u015eah\u0130n O (2020) Additional benefit of canakinumab on proteinuria in a case with Muckle-Wells syndrome in remission under anakinra. Arch Rheumatol 35:149\u2013150. https:\/\/doi.org\/10.5606\/ArchRheumatol.2020.7378","journal-title":"Arch Rheumatol"},{"key":"6130_CR11","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/nri2725","volume":"10","author":"J Tschopp","year":"2010","unstructured":"Tschopp J, Schroder K (2010) NLRP3 inflammasome activation: the convergence of multiple signalling pathways on ROS production? Nat Rev Immunol 10:210\u2013215. https:\/\/doi.org\/10.1038\/nri2725","journal-title":"Nat Rev Immunol"},{"key":"6130_CR12","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1146\/annurev-pathol-020712-163913","volume":"10","author":"GT Westermark","year":"2015","unstructured":"Westermark GT, F\u00e4ndrich M, Westermark P (2015) AA amyloidosis: pathogenesis and targeted therapy. Annu Rev Pathol 10:321\u2013344. https:\/\/doi.org\/10.1146\/annurev-pathol-020712-163913","journal-title":"Annu Rev Pathol"},{"key":"6130_CR13","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1093\/ndt\/gfw305","volume":"32","author":"M Nuvolone","year":"2017","unstructured":"Nuvolone M, Merlini G (2017) Systemic amyloidosis: novel therapies and role of biomarkers. Nephrol Dial Transplant 32:770\u2013780. https:\/\/doi.org\/10.1093\/ndt\/gfw305","journal-title":"Nephrol Dial Transplant"},{"key":"6130_CR14","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1080\/14397595.2018.1457469","volume":"29","author":"O Varan","year":"2019","unstructured":"Varan O, Kucuk H, Babaoglu H et al (2019) Efficacy and safety of interleukin-1 inhibitors in familial Mediterranean fever patients complicated with amyloidosis. Mod Rheumatol 29:363\u2013366. https:\/\/doi.org\/10.1080\/14397595.2018.1457469","journal-title":"Mod Rheumatol"},{"key":"6130_CR15","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1002\/acr.23446","volume":"70","author":"S Akar","year":"2018","unstructured":"Akar S, Cetin P, Kalyoncu U et al (2018) Nationwide experience with off-label use of interleukin-1 targeting treatment in familial Mediterranean fever patients. Arthritis Care Res (Hoboken) 70:1090\u20131094. https:\/\/doi.org\/10.1002\/acr.23446","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"6130_CR16","doi-asserted-by":"publisher","first-page":"3892","DOI":"10.1093\/rheumatology\/keaa211","volume":"59","author":"S Ugurlu","year":"2020","unstructured":"Ugurlu S, Ergezen B, Egeli BH et al (2020) Safety and efficacy of anti-interleukin-1 treatment in 40 patients, followed in a single centre, with AA amyloidosis secondary to familial Mediterranean fever. Rheumatology (Oxford) 59:3892\u20133899. https:\/\/doi.org\/10.1093\/rheumatology\/keaa211","journal-title":"Rheumatology (Oxford)"},{"key":"6130_CR17","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1002\/art.30149","volume":"63","author":"JB Kuemmerle-Deschner","year":"2011","unstructured":"Kuemmerle-Deschner JB, Tyrrell PN, Koetter I et al (2011) Efficacy and safety of anakinra therapy in pediatric and adult patients with the autoinflammatory Muckle-Wells syndrome. Arthritis Rheum 63:840\u2013849. https:\/\/doi.org\/10.1002\/art.30149","journal-title":"Arthritis Rheum"},{"key":"6130_CR18","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1007\/s00011-020-01354-w","volume":"69","author":"W Xiong","year":"2020","unstructured":"Xiong W, Meng XF, Zhang C (2020) Inflammasome activation in podocytes: a new mechanism of glomerular diseases. Inflamm Res 69:731\u2013743. https:\/\/doi.org\/10.1007\/s00011-020-01354-w","journal-title":"Inflamm Res"},{"key":"6130_CR19","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1056\/NEJMoa070265","volume":"356","author":"HJ Lachmann","year":"2007","unstructured":"Lachmann HJ, Goodman HJ, Gilbertson JA et al (2007) Natural history and outcome in systemic AA amyloidosis. N Engl J Med 356:2361\u20132371. https:\/\/doi.org\/10.1056\/NEJMoa070265","journal-title":"N Engl J Med"}],"updated-by":[{"DOI":"10.1007\/s10067-022-06158-3","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000}}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-022-06130-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-022-06130-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-022-06130-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,10]],"date-time":"2022-06-10T07:15:19Z","timestamp":1654845319000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-022-06130-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,22]]},"references-count":19,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["6130"],"URL":"https:\/\/doi.org\/10.1007\/s10067-022-06130-1","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,22]]},"assertion":[{"value":"25 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2022","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s10067-022-06158-3","URL":"https:\/\/doi.org\/10.1007\/s10067-022-06158-3","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent for case report publication was obtained from the patient.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"TI has received speaking fees from Asahi Kasei. TK has received speaking fees and\/or honoraria from Tanabe Mitsubishi, Kissei, Pfizer, Amgen, Chugai, Daiichi-Sankyo, and Janssen, and received grants and speaking fees from GlaxoSmithKline. HK has received consulting fees, speaking fees, research budget, and\/or honoraria from Astellas, AbbVie, Ayumi, Asahi Kasei, BMS, Chugai, Eisai, Eli Lilly, Daiichi-Sankyo, Janssen, Novartis, Nihon Kayaku, Pfizer, UCB, GlaxoSmithKline, and Santen. YN has received financial support or fees from BMS, Chugai, GlaxoSmithKline, Kissei, Mitsubishi Tanabe, Ono, and Pfizer. HS has received fees from Pfizer, Bristol-Myers Squibb, Eli Lilly, Sanofi, AbbVie, GlaxoSmithKline, Gilead, Boehringer Ingelheim, Jansen, Novartis, Chugai, Takeda, Astellas, Eisai, Asahi Kasei, and Daiichi-Sankyo, and has received research grants from Novartis. KF has received speaking fees and\/or honoraria from Tanabe Mitsubishi, Bristol-Myers Squibb, Eli Lilly, Chugai, Jansen, Pfizer, Ono, AbbVie, Ayumi, Astellas, Sanofi, Novartis, Daiichi Sankyo, Eisai, Asahi Kasei, and AstraZeneca, and has received research grants from Tanabe Mitsubishi, Bristol-Myers Squibb, Eli Lilly, Chugai, Eisai, Tsumura, and Asahi Kasei. The other authors have not received any grants to declare. The Social Cooperation Program, Department of Functional Genomics and Immunological Diseases, was supported by Chugai Pharmaceutical Co., Ltd.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest\/Competing interests"}}]}}